A retrospective review of medical records, microbiology and pathology laboratory records, and nosocomial infection surveillance data was undertaken to describe the experience with culture-documented aspergillus infection in pediatric cancer patients at our facility. Sixty-six patients were identified from a 34-year period. The most common underlying diagnosis was leukemia. Risk factors included neutropenia, immunosuppression, and prior antibiotic therapy. On the basis of clinical presentation, 23 patients were believed to have disseminated disease and 43 to have localized disease. The lung was the most frequently affected organ. Despite aggressive medical and surgical management, overall mortality was 85% within the first year after diagnosis. Patients who presented with disease in sites other than the lungs fared better than patients with initial pulmonary involvement ( ). Aspergillosis con-P = .0014 tinues to be associated with poor outcome. Development of improved medical and adjuvant therapies, including surgery, is warranted.
Aspergillus species are ubiquitous fungi consistently documented as some of the most prevalent airborne molds. Conidia of Aspergillus species are often found in fireproofing or building material and are dispersed by ventilation systems into indoor air, including air within hospitals. Infection is usually initiated by inhalation of airborne conidia [1] [2] [3] [4] . Invasive aspergillosis is an increasingly common fungal infection that primarily affects severely immunocompromised patients, particularly those with prolonged neutropenia and those receiving cancer chemotherapy, high-dose corticosteroids, or broad-spectrum antibiotics [5] [6] [7] . Patients undergoing solid organ or bone marrow transplantation with associated immune suppression and patients with AIDS are also at increased risk [8] [9] [10] [11] . Aspergillus species are second only to Candida species as the cause of opportunistic mycoses in immunocompromised hosts [12] .
Invasive aspergillus infections in adults have been well characterized [13] [14] [15] ; however, only a few small studies of aspergillosis in children have been reported [16] [17] [18] [19] . We reviewed patient records from a 34-year period at St. Jude Children's Research Hospital (Memphis) and identified 66 patients with culture-documented aspergillosis. Our objective was to examine the epidemiological, microbiological, clinical, and therapeutic features of these cases and to determine if any aspects were unique to immunocompromised children.
Materials and Methods
Patient population. St. Jude Children's Research Hospital is a tertiary referral center for pediatric patients with certain malignancies, hematologic disorders, and AIDS. Between 1962 and 1996, ∼9500 children and adolescents received therapy for malignancies or hematologic disorders at St. Jude. Bone marrow transplantation has been performed since 1982.
Identification and case definition. Cases of invasive aspergillosis were identified by review of nosocomial infection surveillance data, pathology reports, microbiological studies, and patient records for the period between February 1962, when the hospital opened, and February 1996. Patients were included only if there was evidence of invasive aspergillosis, as determined by isolation of Aspergillus species in culture and a compatible clinical illness, with or without histopathologic evidence of invasive fungal disease. Patients were excluded if the isolate was obtained from a nonsterile site, in the absence of histopathologic evidence of invasion or a compatible clinical illness. Patients were also excluded if there was histopathologic evidence of invasive fungal infection with septate hyphae but cultures failed to yield an organism.
The medical records of identified cases were reviewed for the underlying medical condition; preceding antimicrobial or immunosuppressive therapy, including administration of corticosteroids; the extent and duration of neutropenia; duration of hospitalization; concomitant infections; colonization with Aspergillus species; diagnostic procedures (including biopsies, autopsies, and CT scanning); extent of disease; therapy; and outcome.
Microbiology. Tracheal aspirates, nasopharyngeal specimens, blood, or biopsy specimens obtained from patients with suspected aspergillosis were inoculated onto blood agar and Sabouraud's medium with and without cycloheximide and incubated at 30ЊC for 21 days. Nasal swabs were plated on Sabouraud's medium and incubated at 30ЊC for 14 days. Slide cultures were made of colonies that were suspected to be Aspergillus species, and species were identified by their morphology.
Statistical analysis. Student's t tests were performed with use of SAS, version 6.12 (SAS Institute, Cary, NC). Survival was dis- Demographic characteristics of patients. The ages of the patients (24 females and 42 males) were 1.3-21.6 years (median age, 11.2 years). The most common underlying immunodeficiency was leukemia, which occurred in 56 patients. The remaining 10 patients had other underlying problems (table 1). The incidence of invasive aspergillosis among patients with various underlying disorders treated at St. Jude during this 34-year period was as follows: choriocarcinoma, 6% (1/16); myelodysplastic syndrome, 8% (2/25); chronic granulomatous disease, 7% (1/14); aplastic anemia, 4.6% (2/43); acute nonlymphocytic leukemia, 4% (26/647); chronic myeloid leukemia, 4% (1/24); acute lymphoblastic leukemia, 1% (29/2659); neuroblastoma, 0.17% (1/583); and lymphoma, 0.16% (2/1188).
Epidemiology. The interval between the onset of the underlying disease and the diagnosis of invasive aspergillosis was 0-180 months (median, 16 months). Fifty-two patients (78%) had neutropenia (!500 white blood cells/mm 3 ) and 50 (75%) had received antibiotic therapy for 1-60 days (median, 18.5 days) within the 3-month period before onset of aspergillosis (table 1) . Thirty-two patients (48%) had received corticosteroids in the 3 months before onset of the disease, and 55 (83%) had received some form of chemotherapy in the month before the diagnosis of aspergillosis. Forty-four patients (66%) were hospitalized for 1-52 days (median, 36 days) before the onset of clinically apparent disease; 46 had evidence of concomitant infection with a microorganism other than an Aspergillus species.
In addition to invasive disease, 23 patients (35%) were colonized with Aspergillus species in the nares, pharynx, or rectum. Isolates were identified by species in only 15 cases. In 11 of those cases, the strain with which the patient was colonized corresponded with the disease-causing organism.
Clinical presentation. The initial clinical symptom or abnormality developed a median of 11 days (range, 0-69 days) prior to diagnosis of aspergillosis. Fever was the only presenting symptom in 3 patients. Of the remaining 63 patients, 32 had radiological abnormalities (evident on 28 chest radiographs, 3 chest CT images, and 1 sinus radiograph), noted during investigation of unexplained fever with or without neutropenia. The remaining 31 had clinical findings suggestive of disease, including skin lesions (11 patients), facial swelling or increased nasal drainage (8) , respiratory symptoms or chest pain (7), headache (3), hip pain (1), or pericardial effusion (1) .
At the time of diagnosis of aspergillosis, many patients had evidence of infection-suggested by clinical signs, symptoms, or images-in multiple sites. The most common site of infection was the lung. Lung involvement was observed in 46 patients (70%), whereas sinus disease was evident in 12 patients (18%) (table 2). One patient had both pulmonary and sinus disease at presentation. Skin lesions were present in 13 patients (20%). Two patients had bone disease and 2 had evidence of cardiac involvement at initial presentation.
Of the 6 patients with autopsy evidence of liver involvement by aspergillosis, 4 had undergone imaging studies of the abdomen before their deaths. Two were negative, 1 showed evidence of hepatic abscesses, and another showed evidence of hepatomegaly. Of the 27 patients with no evidence of liver in- volvement at autopsy, 12 had undergone prior imaging studies of the abdomen. Two showed evidence of hypodense lesions in the liver, 1 showed hepatomegaly, and 9 were negative. Of the 5 patients with autopsy evidence of splenic disease, 4 had undergone prior imaging studies of the abdomen, and only 1 showed evidence of splenic abscesses. Of the 7 patients who had autopsy evidence of kidney disease, 5 had undergone prior imaging studies, and all of these were negative for kidney disease.
For the purposes of further description of our patients, we elected to categorize them into 2 broad categories according to whether they had disseminated or localized aspergillosis. Patients were assigned to these categories on the basis of presenting clinical features, including symptoms and findings of histology, culture, and imaging. Patients in the disseminated aspergillosis category ( ) had у2 sites of clinical involven = 23 ment or the documented presence of Aspergillus in the blood. Patients in the localized aspergillosis category ( ) had only n = 43 1 site of clinical involvement. The sites were lungs (26 patients), sinus (9), skin (6), and bone (2). Among those categorized on the basis of clinical features as having localized disease, 14 had evidence of dissemination at autopsy. For the remainder of this report, patients are categorized as described above.
Disseminated aspergillosis. Twenty-three patients (35%), all but 3 of whom had lung involvement, had clinical evidence of disseminated aspergillosis. The most common site of clinically apparent dissemination from the lungs was the brain (9 patients; 39%). Symptoms of CNS disease included disorientation, somnolence, blurred vision, and weakness. Seven (30%) of the patients had evidence of cutaneous disease. For all but 1 patient, the diagnosis of skin disease preceded that of pulmonary disease. The other sites that were involved included the liver (3 patients), heart (2), spleen (2), kidney (1), bone (2), and sinus (3).
Intra-abdominal disease (liver, spleen, and kidney) was diagnosed on the basis of abdominal imaging findings. Of the 2 patients with cardiac disease, 1 presented with pericardial effusion, and the second had an intracardiac thrombus from which Aspergillus was isolated. The latter had destructive changes in the lumbar vertebrae evident on imaging but no related symptoms. The infection of a patient with chronic granulomatous disease had extended to involve the chest wall (rib and vertebral body). Direct extension of infection to cavernous sinus disease and CNS involvement occurred in a patient who presented with pansinusitis.
Four patients had positive blood cultures for Aspergillus species, and all died. The initial clinical presentation of 3 of these 4 patients was fever with neutropenia, and the fourth had pansinusitis. These symptoms preceded diagnosis by 8, 17, 31, and 44 days, respectively; death followed diagnosis of aspergillosis by 16, 21, 23 , and 55 days, respectively. Autopsies confirmed disease with Aspergillus in 3 of the 4 patients; no postmortem examination was performed on the fourth patient.
The diagnosis of aspergillosis was made before death for 16 patients with disseminated disease. These diagnoses were made on the basis of the findings of skin culture (5 patients), blood culture (4), nasopharyngeal culture (2), lung biopsy culture (1), cardiac thrombus culture (1), pericardial fluid culture (1), sphenoid sinus culture (1), and bone culture (1). For the remaining 7 patients, the definitive diagnosis was made at autopsy.
Localized aspergillosis: pulmonary disease. Of the 43 patients (65%) with localized disease, 26 (60%) had clinical evidence of pulmonary disease only. These patients had cough, dyspnea, tachypnea, chest pain, or abnormal chest radiographs. The diagnosis was made before death for 13 patients and was based on findings of tracheal aspirate culture (6), lung biopsy culture (4), lung needle aspirate culture (2), and pleural fluid culture (1). Definitive diagnosis was made at autopsy for the remaining 13.
Sinus disease. Nine patients (20% of those with localized disease) had sinus involvement by aspergillosis as the only manifestation of the disease. The diagnosis of sinus disease was made on the basis of symptoms of sinusitis (nasal congestion, discharge, headache, and facial swelling) and abnormal sinus radiographs. Four patients had pansinusitis, 3 had both maxillary and ethmoid involvement, and 2 had maxillary involvement only. Diagnoses were established before death on the basis of findings of sinus cultures (4 patients), nasopharyngeal cultures (4), and eye culture (1). In 1 patient with clinically localized sinus disease, dissemination to the lung and brain was noted at autopsy.
Skin disease. Six patients had localized cutaneous aspergillosis. Nodular, necrotic, crusted, or ecchymotic lesions with surrounding erythema or cellulitis developed at sites of trauma and were commonly related to armboard or intravenous sites. Aspergillus species were isolated from the skin lesions of all patients; however, for 1 patient, the definitive diagnosis was made at autopsy. The skin biopsy specimens from 5 of the 6 patients were histopathologically examined. All specimens showed evidence of inflammation, with necrosis of epidermis and fibroadipose tissue. Septate mycelial fungal organisms branching at 45Њ were present in all but 1 of the specimens.
Bone disease. Two patients had disease confined to the bone. One patient had osteomyelitis of the proximal femur with right hip pain and was unable to walk; the other had calcaneal osteomyelitis with overlying cellulitis.
Therapy and outcome. Of the 66 patients, 56 (85%) died within 1 year ( figure 1A ), but thereafter no deaths occurred. Survival was similar for patients with localized versus disseminated disease, categorized on the basis of clinical features (figure 1B; ). Patients with initial pulmonary disease, in-P = .71 cluding those categorized as having localized disease, fared significantly worse than those without pulmonary disease (figure 1C; ). Among the 10 survivors, the median dose P = .0014 for antifungal therapy was 25.5 mg/kg (range, 0-37 mg/kg).
Disseminated aspergillosis. Of the patients with dissemi- ) . P = .0014 nated aspergillosis, all except 2 were treated with amphotericin B (total cumulative dose range, 1.5-72.5 mg/kg; median, 13.5 mg/kg) over a period of 3-68 days (median, 20 days). Eight patients received 5-flucytosine (5FC) for 1-50 days (median, 11.5 days), whereas 8 received rifampin for 2-30 days (median, 6 days). Six patients received both rifampin and 5FC. One of these patients received leukocyte transfusions, 1 received granulocyte macrophage colony stimulating factor (GM-CSF), 1 received ketoconazole, and another received itraconazole in addition to amphotericin B. Six of the 23 patients with disseminated infection underwent surgery: antrostomy/sinus drainage for sinus disease (2), right sphenoidectomy (1), intracardiac thrombectomy for mitral valve thrombus (1), rib resection (1), and segmental pulmonary resection (1) .
Only 1 of the 23 patients with disseminated infection survived. Autopsy was done on 12 patients, and all confirmed disseminated aspergillus infection. Several had aspergillus involvement of organs that was not suspected clinically before their deaths (table 2). For the 10 patients on whom autopsies were not performed, the cause of death seemed to be progressive aspergillosis in 9 and progression of the underlying disease in 1.
Localized aspergillosis: pulmonary disease. Nineteen of the 26 patients with localized disease received a total cumulative dose of 0.25-63 mg/kg (median, 22 mg/kg) of amphotericin B over 1-126 days (median, 47 days). Seven of these patients received 5FC for 3-34 days (median, 7 days), whereas 8 received rifampin for 2-38 days (median, 10 days). One received both rifampin and 5FC. Seven underwent pulmonary surgery (either lobectomy or segmental resection); of these, 1 had a bilateral thoracotomy. In addition, 1 patient received leukocyte transfusion, 1 received GM-CSF, and one received itraconazole.
Of the 26 patients with clinically localized pulmonary disease, only 1 survived beyond 1 year. Of the 25 patients who died, autopsies were performed on 21 (84%). Three had no evidence of fungal disease at autopsy. Pulmonary aspergillosis was confirmed in all the remaining 18 patients. In addition, 11 (61%) of these 18 patients with clinically localized disease were discovered to have disseminated infection, whereas the other 7 (38%) had infection localized to lungs only, as clinically suspected before their deaths. Autopsies were not done on 4 patients, but for 2 of these, progressive aspergillosis appeared to be the main cause of death. The remaining 2 patients appeared to have died of multifactorial causes, including aspergillosis.
Sinus disease. All patients with focal sinus disease received amphotericin B for 7-55 days (median, 27 days), for a total cumulative dose of 7-29 mg/kg (median, 23 mg/kg). Four of these patients received 5FC for 1-40 days (median, 3 days), and 4 received rifampin for 4-30 days (median, 22 days). One received both 5FC and rifampin. Three patients had amphotericin B nasal washes in addition to other treatment. Six underwent a surgical procedure.
Five of the 9 patients with clinically localized sinus infection died. Autopsies were done on 2. One patient had no evidence of fungal disease at autopsy, and one had evidence of disseminated infection involving sites other than sinus (lung, brain, and mediastinum). Of the 3 patients who were not autopsied, 2 appeared to have died of progressive aspergillosis, and 1 died of multifactorial causes, including aspergillosis. Skin disease. All patients except 1 in this group received amphotericin B for 6-50 days (median, 17 days), for a total cumulative dose of 6-40 mg/kg (median 17 mg/kg). Three of these patients also received 5FC for 5-16 days (median, 12 days). One patient received rifampin for 5 days in addition to amphotericin B and 5FC. The patient who did not receive any antifungal treatment had developed skin lesions at the bone marrow aspiration site, over both anterior and posterior iliac spines. Treatment was not initiated, since the isolate was initially believed to be a contaminant; however, local debridement was done, and the lesion healed. None of the other patients had surgical debridement done.
Three of the 6 patients with clinically localized cutaneous infection died. Autopsies showed that 2 had evidence of disseminated infection, whereas 1 had no evidence of fungal disease.
Bone disease. Both patients with localized bone disease had surgical debridement of the diseased bone. They received amphotericin B for 41 days and 56 days, respectively. In addition, 1 received both 5FC and rifampin. The patient with osteomyelitis of the proximal femur recovered, but the patient who had osteomyelitis of the calcaneus died. An autopsy was not done, but the patient appeared to have died of multifactorial causes, including aspergillosis.
Toxicity. Overall, 19 patients (28%) developed nephrotoxicity, whereas 6 had hypokalemia secondary to amphotericin B therapy. One patient had severe respiratory distress syndrome believed to be temporally related to amphotericin B therapy. Nine patients (14%) in our series had evidence of liver toxicity, with direct hyperbilirubinemia and moderately elevated transaminase levels. The cause of this was believed to be multifactorial, including drug toxicity and perhaps aflatoxin production by some Aspergillus species. The majority of the patients who had hepatotoxicity had infection with A. flavus (55%), similar to the proportion of patients without hepatotoxicity.
Discussion
Certain host factors have been reportedly associated with invasive aspergillosis in adults [7, 13, 14] , and these factors were also present in our pediatric cases. The most common underlying disease was leukemia, present in 85% of the patients, which reflects the large number of children with leukemia who are treated at our institution. Most patients had been neutropenic at the time of diagnosis of the fungal infection; the median duration of neutropenia was ∼2 weeks. As in previous reports [20, 21] , prior chemotherapy (83%) and corticosteroid therapy (48%) appeared to be additional risk factors.
Broad-spectrum antibiotic therapy also has been considered a major risk factor, and 75% of patients in our series had received some form of antibiotic therapy in the preceding 3 months. The median duration of antibiotic therapy was 18.5 days. The majority of our patients had been hospitalized (median, 36 days) before the onset of the infection. Concomitant bacterial, fungal, and viral infections were present in 70% of the patients at the time aspergillosis was diagnosed; bacterial infection was the most common.
Isolation of Aspergillus species from nasal cultures has been suggested to be highly predictive of invasive aspergillosis in patients with acute nonlymphocytic leukemia [22] . The usefulness of isolates from other respiratory sites in predicting aspergillus infection has been debated. Reported predictive values of sputum isolation were 13%-67% [23] [24] [25] . At our institution, routine surveillance cultures of specimens from the nares, pharynx, and rectum showed that one-third of the patients in this series were colonized with Aspergillus species in the respiratory tract or rectum. Among the isolates for which the species was identified, there was a high correlation (73%) with the species causing disease.
Although 1150 species of Aspergillus have been identified, !20 are known to be pathogenic in humans [5] . In our series, the most commonly isolated species were A. flavus and A. fumigatus. In general, skin and bone diseases were caused by A. flavus, whereas pulmonary and sinus diseases were caused by A. flavus and A. fumigatus, with equal frequency. A. nidulans is 1 of several species of low pathogenicity. Significant infections with A. nidulans have occurred almost exclusively in patients with chronic granulomatous disease [26] . In our series, the only patient infected with this organism had chronic granulomatous disease as his underlying disorder. Because Aspergillus spores are typically airborne, the most common site of invasive aspergillosis in the immunocompromised patients is the lungs. Invasive pulmonary aspergillosis may take many forms, including acute necrotizing bronchopneumonia, hemorrhagic pulmonary infarction, lung abscess, lobar pneumonia, solitary nodule, bronchitis, or pleural effusion. The most common manifestations described have been necrotizing bronchopneumonia and hemorrhagic infarction [6, 7] . In our series, pulmonary involvement was present at some stage of the disease in ∼70% of the patients, the majority of whom developed disseminated disease.
In our series, 18% of the patients had clinical evidence of sinus disease, which is similar to the incidence described in adults. As noted in adults, maxillary and ethmoid sinuses were most commonly involved. Aspergillus species infecting the sinuses may erode natural barriers such as cartilage and bone and cause intracerebral and major arterial infections [27] . Two of our 12 patients with sinus infection developed this complication.
The cutaneous presentation of aspergillosis appears to be more common in children [19] . In our series, 13 patients (20%) had evidence of cutaneous infection. The fact that armboards are used more commonly with children than with adults, to stabilize intravenous infusion sites, may help explain this observation. The lesion may develop from direct inoculation of the fungus from an environmental source as a result of trauma or may result from localization of Aspergillus species to areas of stasis during fungemia. In approximately one-third of our patients with cutaneous aspergillosis, infection disseminated to involve the lungs, brain, heart, thyroid, pancreas, gastrointestinal tract, or kidney.
Skin may have been the portal of entry in patients with disseminated aspergillosis, or skin lesions may have been a manifestation of disseminated disease. These cutaneous lesions initially presented as erythematous or edematous plaques that progressed to necrotic ulcers with black eschar or hemorrhagic bullae.
In 2 patients, the primary site of infection was bone, a less common but previously described site of aspergillus infection, both primary as well as secondary to dissemination [28] . Cardiovascular aspergillosis is usually a postoperative infection following implantation of a prosthetic valve or homograft, and patients present with either endocarditis or myocarditis [6] . Pericarditis resulting from contiguous dissemination of Aspergillus species from lung or myocardium has also been described [29] . Two of our patients had premortem evidence of cardiac involvement by Aspergillus species. One had pericarditis, and the other had endocarditis. Nine other patients had evidence of aspergillus endocarditis, myocarditis, and/or pericarditis only at postmortem. Isolation of Aspergillus from blood was rare, even for patients with cardiac disease. The mortality rate was 100%.
The brain is one of the more frequent sites of aspergillus infection. Most intracranial infections are secondary, however, with the primary site of infection located in the lungs, sinuses, or skin. Dissemination to the CNS occurs via the circulatory system or by direct extension from the sinuses. Four primary types of CNS aspergillosis have been described: meningitis, meningoencephalitis, multiple brain abscesses, and single brain abscess [30, 31] . Nine patients in our series had premortem evidence of CNS involvement, with the primary focus in the lungs or the sinuses. There was evidence of CNS disease in 13 (39%) of the 33 patients who had evidence of aspergillosis at autopsy.
CT scans are believed to play an important role in improving survival rate by permitting early diagnosis and treatment of invasive aspergillosis [32] . We assessed the usefulness of CT scans of the abdomen and head for diagnosis of dissemination. CT scans of the heads of patients with neurological symptoms were useful in the diagnosis of intracranial lesions (data not shown). However, in our series, the sensitivity of CT scanning of the abdomen for diagnosis of intra-abdominal aspergillosis appeared to be limited for hepatic disease and very poor for splenic or kidney disease.
Prior data suggest that success in treatment of aspergillosis is related to early diagnosis, aggressive antifungal therapy, wide debridement, and recovery from neutropenia [15] . In our experience, one strong predictor of outcome was the site of involvement. Those who had only nonpulmonary sites of infection at presentation had a much better outcome, with survival rates of 40%, but those with initial pulmonary disease had a survival rate of ∼3% ( figure 1C; ). Better outcome for P = .0014 patients with nonpulmonary disease may reflect the fact that diagnosis occurs earlier than for those with pulmonary disease, allowing earlier initiation of therapy.
In the category of localized disease, the median time from onset of symptoms until diagnosis was significantly less for patients with nonpulmonary foci than for those with localized pulmonary disease (4 vs. 11 days; Student's t test, ). In P ! .05 addition, patients with localized disease in the skin or sinuses were likely to undergo early debridement of focal infected tissue, potentially preventing dissemination. It can also be speculated that local host defenses are superior in nonpulmonary sites.
It is noteworthy that outcome was similar for patients with disseminated versus localized disease at presentation ( figure 1B; ). The strikingly high mortality in our series of patients P = .71 may reflect, in part, the stringent criterion of culture-proved infection required for inclusion in this study. Patient series that include suspected cases may include mild cases and cases that mimic aspergillosis but are caused by other, possibly less virulent pathogens.
Outcome did not appear to be related to either the duration or dosage of amphotericin B therapy or to the addition of other antifungals, such as itraconazole, rifampin, or 5FC. Although amphotericin B remains the drug of choice for treatment of most forms of invasive aspergillosis, our overall survivor rate (15%) was dismal. Data suggest that liposomal amphotericin [33, 34] and itraconazole [35] [36] [37] may be effective in some cases. Clearly, additional antifungal agents are needed for medical management of this disease. Attempts to enhance host defenses are still in the preliminary stages, but some encouraging results have been reported [38] .
Given the devastating consequences of invasive aspergillosis, prevention remains a major goal. Intranasal instillation and intravenous infusions of amphotericin B for prophylaxis [39] have been studied but remain controversial, as have the combination of intranasal amphotericin B and oral itraconazole [40] and itraconazole alone [41, 42] . The control and filtering of air flow in the hospital room has also been shown to be another potential prophylactic measure [43] .
The effect of surgery on outcome is not clear. Of the 7 patients with localized pulmonary infection who underwent surgical resection of infected lung, 1 recovered, and 2 had no evidence of fungal disease at autopsy. Of the patients with localized sinus disease, 6 underwent drainage procedures. Among these the mortality was 50%. A similar mortality rate with surgery was observed for the 2 patients with localized bone disease. These data suggest, but do not prove, an added benefit of surgical resection or drainage but only in localized disease.
Autopsies were done on 38 of the 56 patients who died. The autopsies showed aspergillosis in 33 of these patients but no evidence of aspergillosis in the remaining 5. Before their deaths, 24 of these patients were thought to have only localized disease, but 15 had disseminated disease at autopsy. The determination of dissemination in patients with clinically apparent localized disease was documented only because of the high autopsy rate in this series (68%).
The cause of death for the 18 patients on whom autopsies were not performed appeared to be progressive aspergillosis in 9, progression of underlying disease in 3, multiple factors (including aspergillosis) in another 3, and unknown factors in the remaining 3. Hence, aspergillosis either was present at autopsy or was thought to be a factor contributing to the deaths of 45 patients.
The interval between diagnosis of infection and death for the 56 patients who died was 3-312 days (median, 29 days). Six patients initially recovered, and their disease cleared; however, they had a recurrence and died after 67-290 days (median, 200 days). Therefore, follow-up of at least 6-10 months is important for the diagnosis of late recurrence. Unlike findings described in earlier reports, the long-term follow-up of patients in our study revealed a high mortality rate. At the end of 1 month, 58% of the patients in our study had survived, and after 2 months 25% had survived. However, only 15% had survived by the end of 10 months. Careful attention to the duration of follow-up in published series is important for evaluation of new management regimens.
Although uncommon in pediatric patients, aspergillosis remains a serious complication of immunosuppression associated with treatment for cancer. Features of disease in children were similar to those previously noted in adults. Despite early diagnosis and aggressive management, long-term outcome of this disease was poor at our institution during the study period. Lung disease at presentation was associated with the worst outcome.
Localized disease, except in the lung, is associated with better outcome. A large proportion of patients with clinically localized disease were found to have unsuspected disseminated disease at autopsy. Our data also suggest that diagnosis of localized disease followed by surgical resection of infected tissue has the potential to improve chance of survival, but further investigation of this strategy is necessary. Development of more effective antifungal agents is needed to improve the outcome for these patients, many of whom are curable of cancer.
